keyword
MENU ▼
Read by QxMD icon Read
search

CTC AND prostate cancer

keyword
https://www.readbyqxmd.com/read/28904887/biology-and-clinical-significance-of-circulating-tumor-cell-subpopulations-in-lung-cancer
#1
REVIEW
Linda O'Flaherty, Harriet Wikman, Klaus Pantel
By identifying and tracking genetic changes in primary tumors and metastases, patients can be stratified for the most efficient therapeutic regimen by screening for known biomarkers. However, retrieving tissues biopsies is not always feasible due to tumor location or risk to patient. Therefore, a liquid biopsies approach offers an appealing solution to an otherwise invasive procedure. The rapid growth of the liquid biopsy field has been aided by improvements in the sensitivity and specificity of enrichment assays for isolating circulating tumor cells (CTCs) from normal surrounding blood cells...
August 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28903443/radioligand-therapy-of-metastatic-prostate-cancer-using-177-lu-psma-617-after-radiation-exposure-to-223-ra-dichloride
#2
Hojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, Rolf Fimmers, Stefan Kürpig, Elisabeth Eppard, Florian C Gaertner, Xiao Wei, Stefan Hauser, Markus Essler
Radioligand therapy with (177)Lu-PSMA-617 is an innovative and effective therapy for castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone metastases without visceral metastases, the guidelines recommend radionuclide therapy with (223)Ra-dichloride as a single therapeutic agent or in combination with hormone therapy. The aim of this study was to evaluate the safety of repeated cycles of (177)Lu-PSMA-617 after exposure to more cycles of (223)Ra. Forty-nine patients were treated with three cycles of Lu-PSMA-617 divided into two groups subjected to a history of therapy with (223)Ra...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28903376/improving-circulating-tumor-cells-enumeration-and-characterization-to-predict-outcome-in-first-line-chemotherapy-mcrpc-patients
#3
Luis León-Mateos, Helena Casas, Alicia Abalo, María Vieito, Manuel Abreu, Urbano Anido, Antonio Gómez-Tato, Rafael López, Miguel Abal, Laura Muinelo-Romay
INTRODUCTION: There is a critical need of new surrogate markers for improving the therapeutic selection and monitoring of metastatic prostate cancer patients. Nowadays clinical management of these patients is been driven by biochemical and clinical parameters without enough accuracy to allow a real personalized medicine. The present study was conducted to go insight the molecular profile of circulating tumor cells (CTCs) isolated from advanced metastatic castration-resistant prostate cancer (mCRPC) with the aim of identifying prognostic marker with potential utility for therapy selection and monitoring...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28895565/prostate-cancer-ctc-phenotype-informs-treatment-type
#4
Louise Stone
No abstract text is available yet for this article.
September 12, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28892262/glycan-stimulation-enables-purification-of-prostate-cancer-circulating-tumor-cells-on-pedot-nanovelcro-chips-for-rna-biomarker-detection
#5
Mo-Yuan Shen, Jie-Fu Chen, Chun-Hao Luo, Sangjun Lee, Cheng-Hsuan Li, Yung-Ling Yang, Yu-Han Tsai, Bo-Cheng Ho, Li-Rong Bao, Tien-Jung Lee, Yu Jen Jan, Ya-Zhen Zhu, Shirley Cheng, Felix Y Feng, Peilin Chen, Shuang Hou, Vatche Agopian, Yu-Sheng Hsiao, Hsian-Rong Tseng, Edwin M Posadas, Hsiao-Hua Yu
A glycan-stimulated and poly(3,4-ethylene-dioxythiophene)s (PEDOT)-based nanomaterial platform is fabricated to purify circulating tumor cells (CTCs) from blood samples of prostate cancer (PCa) patients. This new platform, phenylboronic acid (PBA)-grafted PEDOT NanoVelcro, combines the 3D PEDOT nanosubstrate, which greatly enhances CTC capturing efficiency, with a poly(EDOT-PBA-co-EDOT-EG3) interfacial layer, which not only provides high specificity for CTC capture upon antibody conjugation but also enables competitive binding of sorbitol to gently release the captured cells...
September 11, 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/28883519/monolithic-chip-for-high-throughput-blood-cell-depletion-to-sort-rare-circulating-tumor-cells
#6
Fabio Fachin, Philipp Spuhler, Joseph M Martel-Foley, Jon F Edd, Thomas A Barber, John Walsh, Murat Karabacak, Vincent Pai, Melissa Yu, Kyle Smith, Henry Hwang, Jennifer Yang, Sahil Shah, Ruby Yarmush, Lecia V Sequist, Shannon L Stott, Shyamala Maheswaran, Daniel A Haber, Ravi Kapur, Mehmet Toner
Circulating tumor cells (CTCs) are a treasure trove of information regarding the location, type and stage of cancer and are being pursued as both a diagnostic target and a means of guiding personalized treatment. Most isolation technologies utilize properties of the CTCs themselves such as surface antigens (e.g., epithelial cell adhesion molecule or EpCAM) or size to separate them from blood cell populations. We present an automated monolithic chip with 128 multiplexed deterministic lateral displacement devices containing ~1...
September 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28868131/circulating-tumor-cells-silent-predictors-of-metastasis
#7
REVIEW
LanLan Zhou, David T Dicker, Elizabeth Matthew, Wafik S El-Deiry, R Katherine Alpaugh
Circulating tumor cells (CTCs) were added to the arsenal of clinical testing in 2004 for three cancer types: metastatic breast, prostate, and colorectal cancer. CTCs were found to be an independent prognostic indicator of survival for these three diseases. Multiple enrichment/isolation strategies have been developed and numerous assay applications have been performed using both single and pooled captured/enriched CTCs. We have reviewed the isolation techniques and touched on many analyses. The true utility of a CTC is that it acts as a "silent" predictor of metastatic disease...
2017: F1000Research
https://www.readbyqxmd.com/read/28856701/extracellular-vesicles-for-personalized-therapy-decision-support-in-advanced-metastatic-cancers-and-its-potential-impact-for-prostate-cancer
#8
REVIEW
Carolina Soekmadji, Niall M Corcoran, Irina Oleinikova, Lidija Jovanovic, Grant A Ramm, Colleen C Nelson, Guido Jenster, Pamela J Russell
The use of circulating tumor cells (CTCs) and circulating extracellular vesicles (EVs), such as exosomes, as liquid biopsy-derived biomarkers for cancers have been investigated. CTC enumeration using the CellSearch based platform provides an accurate insight on overall survival where higher CTC counts indicate poor prognosis for patients with advanced metastatic cancer. EVs provide information based on their lipid, protein, and nucleic acid content and can be isolated from biofluids and analyzed from a relatively small volume, providing a routine and non-invasive modality to monitor disease progression...
August 29, 2017: Prostate
https://www.readbyqxmd.com/read/28843267/screening-for-circulating-tumour-cells-allows-early-detection-of-cancer-and-monitoring-of-treatment-effectiveness-an-observational-study
#9
Karin Ried, Peter Eng, Avni Sali
Background: Circulating-Tumour-Cells (CTC) provide a blood biomarker for early carcinogenesis, cancer progression and treatment effectiveness. An increase in CTCs is associated with cancer progression, a CTC decrease with cancer containment or remission. Several technologies have been developed to identify CTC, including the validated Isolation-by-Size-of-Epithelial-Tumour (ISET, Rarecells) technology, combining blood filtration and microscopy using standard histo-pathological criteria. Methods: This observational study compared CTC count to cancer status and cancer risk, by monitoring treatment effectiveness in cancer patients and by screening for CTC in asymptomatic patients with risk factors, including family history of cancer...
August 27, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28836508/circulating-tumor-cells-and-their-role-in-prostate-cancer
#10
REVIEW
Moritz Maas, Miriam Hegemann, Steffen Rausch, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer
Circulating tumor cells (CTC) have become an important biomarker in patients with advanced prostate cancer. CTC count has been demonstrated to be a prognostic factor for overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). In localized prostate cancer, a clear correlation between CTC counts and clinicopathological risk parameters and outcome has not been observed. Currently, the focus of research is shifting from CTC enumeration towards molecular characterization of CTC leading to the discovery of markers predicting treatment response...
August 22, 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/28819021/phenotypic-heterogeneity-of-circulating-tumor-cells-informs-clinical-decisions-between-ar-signaling-inhibitors-and-taxanes-in-metastatic-prostate-cancer
#11
Howard I Scher, Ryon P Graf, Nicole Schreiber, Brigit McLaughlin, Adam Jendrisak, Yipeng Wang, Jerry Lee, Stephanie Greene, Rachel Krupa, David Lu, Pascal Bamford, Jessica Louw, Lyndsey Dugan, Hebert Alberto Vargas, Martin Fleisher, Mark Landers, Glenn Heller, Ryan V Dittamore
The heterogeneity of an individual patient's tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical setting are currently lacking. Using established tools available in a CAP-accredited and CLIA-certified clinical laboratory, we quantified digital pathology features on 9,225 individual circulating tumor cells (CTCs) from 179 unique metastatic castration-resistant prostate cancer (mCRPC) patients to define phenotypically distinct cell types...
August 17, 2017: Cancer Research
https://www.readbyqxmd.com/read/28818355/ar-v7-in-peripheral-whole-blood-of-patients-with-castration-resistant-prostate-cancer-association-with-treatment-specific-outcome-under-abiraterone-and-enzalutamide
#12
Anna Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, Roman Nawroth, Robert Tauber, Mark Thalgott, Sebastian Schmid, Ramona Secci, Margitta Retz, Jürgen E Gschwend, Jürgen Ruland, Christof Winter, Matthias M Heck
BACKGROUND: It has been demonstrated that androgen receptor splice variant 7 (AR-V7) expression in circulating tumor cells (CTCs) predicts poor treatment response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide. OBJECTIVE: To develop a practical and robust liquid profiling approach for direct quantification of AR-V7 in peripheral whole blood without the need for CTC capture and to determine its potential for predicting treatment response in mCRPC patients...
August 14, 2017: European Urology
https://www.readbyqxmd.com/read/28809987/label-free-ferrohydrodynamic-cell-separation-of-circulating-tumor-cells
#13
Wujun Zhao, Rui Cheng, Brittany D Jenkins, Taotao Zhu, Nneoma E Okonkwo, Courtney E Jones, Melissa B Davis, Sravan K Kavuri, Zhonglin Hao, Carsten Schroeder, Leidong Mao
Circulating tumor cells (CTCs) have significant implications in both basic cancer research and clinical applications. To address the limited availability of viable CTCs for fundamental and clinical investigations, effective separation of extremely rare CTCs from blood is critical. Ferrohydrodynamic cell separation (FCS), a label-free method that conducted cell sorting based on cell size difference in biocompatible ferrofluids, has thus far not been able to enrich low-concentration CTCs from cancer patients' blood because of technical challenges associated with processing clinical samples...
September 12, 2017: Lab on a Chip
https://www.readbyqxmd.com/read/28753792/interrogating-metastatic-prostate-cancer-treatment-switch-decisions-a-multi-institutional-survey
#14
David Lorente, Praful Ravi, Niven Mehra, Carmel Pezaro, Aurelius Omlin, Alexa Gilman, Miguel Miranda, Pasquale Rescigno, Michael Kolinsky, Nuria Porta, Diletta Bianchini, Nina Tunariu, Raquel Perez, Joaquin Mateo, Heather Payne, Leon Terstappen, Maarten IJzerman, Emma Hall, Johann de Bono
BACKGROUND: Evaluation of responses to treatment for metastatic castration-resistant prostate cancer (mCRPC) remains challenging. Consensus criteria based on prostate-specific antigen (PSA) and clinical and radiologic biomarkers are inconsistently utilized. Circulating tumor cell (CTC) counts can inform prognosis and response, but are not routinely used. OBJECTIVE: To evaluate the use of biomarkers and trends in clinical decision-making in current mCRPC treatment...
October 10, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28670371/circulating-tumor-cells-what-we-know-what-do-we-want-to-know-about-them-and-are-they-ready-to-be-used-in-clinics
#15
Zuzana Bielčiková, Anna Jakabová, Michael Pinkas, Milada Zemanová, Katarína Kološtová, Vladimír Bobek
Circulating tumor cells (CTC) present in peripheral blood are assigned precursors of advanced tumor disease. Simplicity of blood withdrawal procedure adds practically an unlimited possibility of the CTC-monitoring and the advantages of the repeated biopsies over time. CTC got prognostic, predictive and diagnostic status with the technologic advance. Although the clinical utility of CTC has reached the high evidence, the significance of CTC testing was presented in the treatment strategy mostly with palliative intention...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28668277/a-phase-ii-trial-of-aezs-108-in-castration-and-taxane-resistant-prostate-cancer
#16
Steven S Yu, Kanthi Athreya, Stephen V Liu, Andrew V Schally, Denice Tsao-Wei, Susan Groshen, David I Quinn, Tanya B Dorff, Shigang Xiong, Jurgen Engel, Jacek Pinski
BACKGROUND: AEZS-108 (zoptarelin doxorubicin) is a cytotoxic hybrid molecule consisting of doxorubicin covalently coupled with a luteinizing hormone-releasing hormone (LHRH) analogue, which selectively targets doxorubicin to tumor cells expressing LHRH receptors. We report the clinical efficacy of AEZS-108 in a phase II trial in men with metastatic castrate-resistant prostate cancer who had disease progression after taxane-based chemotherapy. PATIENTS AND METHODS: Patients received AEZS-108 210 mg/m(2) intravenously every 3 weeks...
June 8, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28632486/randomized-noncomparative-phase-ii-trial-of-early-switch-from-docetaxel-to-cabazitaxel-or-vice-versa-with-integrated-biomarker-analysis-in-men-with-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer
#17
Emmanuel S Antonarakis, Scott T Tagawa, Giuseppe Galletti, Daniel Worroll, Karla Ballman, Marie Vanhuyse, Guru Sonpavde, Scott North, Costantine Albany, Che-Kai Tsao, John Stewart, Atef Zaher, Ted Szatrowski, Wei Zhou, Ada Gjyrezi, Shinsuke Tasaki, Luigi Portella, Yang Bai, Timothy B Lannin, Shalu Suri, Conor N Gruber, Erica D Pratt, Brian J Kirby, Mario A Eisenberger, David M Nanus, Fred Saad, Paraskevi Giannakakou
Purpose The TAXYNERGY trial ( ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity or resistance to taxanes in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer. Patients and Methods Patients were randomly assigned 2:1 to docetaxel or cabazitaxel. Men who did not achieve ≥ 30% prostate-specific antigen (PSA) decline by cycle 4 (C4) switched taxane. The primary clinical endpoint was confirmed ≥ 50% PSA decline versus historical control (TAX327)...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28615267/the-novel-association-of-circulating-tumor-cells-and-circulating-megakaryocytes-with-prostate-cancer-prognosis
#18
Lei Xu, Xueying Mao, Tianyu Guo, Pui Ying Chan, Greg Shaw, John Hines, Elzbieta Stankiewicz, Yuqin Wang, R Tim D Oliver, Amar Sabri Ahmad, Daniel Berney, Jonathan Shamash, Yong-Jie Lu
To develop an approach for the investigation of different subtypes of circulating tumor cells (CTCs) and other cells to evaluate their potential prognostic value of prostate cancer.<br /><br />Experimental Design: Malignancy of CTCs undergoing epithelial to mesenchymal transition (EMT) was confirmed by repeated Fluorescence in situ hybridization. Subgroups of CTCs in 81 patients with prostate cancer (43 castration resistant and 38 untreated localized) were correlated to disease aggressiveness parameters...
June 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28589907/improving-circulating-tumor-cells-enumeration-and-characterization-to-predict-outcome-in-first-line-chemotherapy-mcrpc-patients
#19
Luis León-Mateos, Helena Casas, Alicia Abalo, María Vieito, Manuel Abreu, Urbano Anido, Antonio Gómez-Tato, Rafael López, Miguel Abal, Laura Muinelo-Romay
INTRODUCTION: There is a critical need of new surrogate markers for improving the therapeutic selection and monitoring of metastatic prostate cancer patients. Nowadays clinical management of these patients is been driven by biochemical and clinical parameters without enough accuracy to allow a real personalized medicine. The present study was conducted to go insight the molecular profile of circulating tumor cells (CTCs) isolated from advanced metastatic castration-resistant prostate cancer (mCRPC) with the aim of identifying prognostic marker with potential utility for therapy selection and monitoring...
May 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28560677/mesenchymal-epithelial-transition-and-circulating-tumor-cells-in-small-cell-lung-cancer
#20
Gerhard Hamilton, Barbara Rath
Cancer patients die of metastatic disease but knowledge regarding individual steps of this complex process of intravasation, spread and extravasation leading to secondary lesions is incomplete. Subpopulations of tumor cells are supposed to undergo an epithelial-mesenchymal transition (EMT), to enter the bloodstream and eventually establish metastases in a reverse process termed mesenchymal-epithelial transition (MET). Small cell lung cancer (SCLC) represents a unique model to study metastatic spread due to early dissemination and relapse, as well as availability of a panel of circulating cancer cell (CTC) lines recently...
2017: Advances in Experimental Medicine and Biology
keyword
keyword
29039
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"